Literature DB >> 30898935

Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy.

Michael J Halaska1, Catherine Uzan2,3, Sileny N Han4, Robert Fruscio5, Karina Dahl Steffensen6, Ben Van Calster7, Hana Stankusova8, Martina Delle Marchette5, Astrid Mephon9, Roman Rouzier10, Petronella O Witteveen11, Patrizia Vergani5, Kristina Van Calsteren7,12, Lukas Rob1, Frederic Amant13,14,15.   

Abstract

BACKGROUND: Treatment of cervical cancer during pregnancy is often complex and challenging. This study aimed to analyze current patterns of practice in the management of pregnant patients diagnosed with cervical cancer.
METHODS: This was a matched cohort study comprising patients managed for cervical cancer during pregnancy from six European centers. Patient information was retrieved from the dataset of the International Network for Cancer, Infertility and Pregnancy from 1990 to 2012. Each center matched its patients with two non-pregnant controls for age (±5 years) and International Federation of Gynecology and Obstetrics (FIGO) 2009 stage. Information on age, histological type, grade, lymphovascular space invasion, stage, tumor size, method of diagnosis, site of recurrence, delivery, date of recurrence, and date of death was recorded. Progression-free survival was compared using multivariable Cox proportional hazards regression.
RESULTS: A total of 132 pregnant patients and 256 controls were analyzed. The pregnant patients (median age 34 years, range 21-43) were diagnosed at a median gestational age of 18.4 weeks of pregnancy (range 7-39). Stage distribution during pregnancy was 14.4% for stage IA, 47.0% for IB1, 18.9% for IB2, and 19.7% for II-IV. For treatment during pregnancy, 17.4% of the patients underwent surgery, 16.7% received neoadjuvant chemotherapy, 26.5% delayed their treatment, 12.9% had a premature delivery, and 26.5% had their pregnancy terminated. Median follow-up was 84 months (67 months for pregnant and 95 months for non-pregnant patients). The unadjusted hazard ratio of pregnancy for progression-free survival was 1.18 (95% confidence interval 0.74 to 1.88).
CONCLUSION: Surgery and chemotherapy is increasingly used in the management of pregnant patients with cervical cancer and prognosis is similar to that of non-pregnant patients. © IGCS and ESGO [2019]. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Year:  2019        PMID: 30898935     DOI: 10.1136/ijgc-2018-000103

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

Review 1.  Good news on the active management of pregnant cancer patients.

Authors:  Susan M Folsom; Teresa K Woodruff
Journal:  F1000Res       Date:  2020-06-01

2.  Management of Cervical Cancer in Pregnant Women: A Multi-Center Retrospective Study in China.

Authors:  Mingzhu Li; Yun Zhao; Mingrong Qie; Youzhong Zhang; Longyu Li; Bei Lin; Ruixia Guo; Zhixue You; Ruifang An; Jun Liu; Zhijun Zhang; Hui Bi; Ying Hong; Shufang Chang; Guoli He; Keqin Hua; Qi Zhou; Qinping Liao; Yue Wang; Jianliu Wang; Xiaoping Li; Lihui Wei
Journal:  Front Med (Lausanne)       Date:  2020-12-07

3.  Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies.

Authors:  Liesbeth Lenaerts; Nathalie Brison; Charlotte Maggen; Leen Vancoillie; Huiwen Che; Peter Vandenberghe; Daan Dierickx; Lucienne Michaux; Barbara Dewaele; Patrick Neven; Giuseppe Floris; Thomas Tousseyn; Lore Lannoo; Tatjana Jatsenko; Isabelle Vanden Bempt; Kristel Van Calsteren; Vincent Vandecaveye; Luc Dehaspe; Koenraad Devriendt; Eric Legius; Kris Van Den Bogaert; Joris Robert Vermeesch; Frédéric Amant
Journal:  EClinicalMedicine       Date:  2021-05-13

4.  Rapid progression of cervical squamous cell carcinoma with delayed treatment in pregnancy.

Authors:  Luke Schmidt; Adam Crosland; Diana Pearre; Jill Tseng; Jennifer Jolley
Journal:  Gynecol Oncol Rep       Date:  2022-03-16

5.  The effect of preserving pregnancy in cervical cancer diagnosed during pregnancy: a retrospective study.

Authors:  Zuoxi He; Chuan Xie; Xiaorong Qi; Zhengjun Hu; Yuedong He
Journal:  BMC Womens Health       Date:  2022-07-25       Impact factor: 2.742

6.  Neoadjuvant Chemotherapy in Pregnant Patients with Cervical Cancer: A Monocentric Retrospective Study.

Authors:  Federica Bernardini; Gabriella Ferrandina; Caterina Ricci; Anna Fagotti; Francesco Fanfani; Anna Franca Cavaliere; Benedetta Gui; Giovanni Scambia; Rosa De Vincenzo
Journal:  Curr Oncol       Date:  2022-08-14       Impact factor: 3.109

7.  Clinical pathological analysis of newly diagnosed malignant pelvic tumors during pregnancy.

Authors:  Ying Jiang; Jing Zhao; Ling Ding; Jinfeng Li; Shuzhen Wang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

8.  Alternative management for gynecological cancer care during the COVID-2019 pandemic: A Latin American survey.

Authors:  Juliana Rodriguez; Angélica Fletcher; Fernando Heredia; Robinson Fernandez; Heidy Ramírez Salazar; Daniel Sanabria; Javier Burbano Luna; Eduardo Guerrero; Marc-Edy Pierre; Gabriel J Rendón; Indira Rosero; Lina María Trujillo; Reitan Ribeiro; Glauco Baiocchi; Aldo Lopez Blanco; Magaly Malca; Jorge Hoegl; Alfredo Borges Garnica; Jorge Lasso de la Vega; Santiago Scasso; Joel Laufer; Erick Estuarto Estrada; Armando Gutierrez Criado; Guillermo Sidney Herbert Nuñez; David Cantú-de Leon; Gonzalo Medina; Luis Pendola Gómez; José Saadi; Florencia Noll; Danilo Arévalo Sandoval; Alexandre Ferreira Oliveira; Rene Pareja
Journal:  Int J Gynaecol Obstet       Date:  2020-07-17       Impact factor: 4.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.